Purpose of the study DRV/r has been evaluated in a large-scale clinical program in a broad range of HIV-1-infected antiretroviral-naïve and -experienced patients (pts). This analysis examines the safety profile of DRV/r in pts in these studies administered DRV/r 600/100 mg BID or 800/100 mg QD, as part of combination therapy.
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Methods
All available safety data at 48 weeks were analysed from 1,376 pts recruited to the DRV/r 600/100 mg BID and 800/100 mg QD arms of Phase IIb POWER 1 + 2 trials and Phase III ARTEMIS, TITAN and DUET trials. In ARTEMIS, treatment-naïve pts received 800/100 mg QD (n = 343) or lopinavir/r (LPV/r) 800/200 mg (total daily dose; n = 346); all pts received tenofovir/emtricitabine. In TITAN, treatment-experienced, LPV-naïve pts received DRV/r 600/100 mg BID (n = 298) or LPV/r 400/100 mg BID (n = 297) + OBR. In POWER 1 + 2, highly treatment-experienced pts who only received DRV/r 600/100 mg BID + OBR (n = 131) were included. Only pts from the control arm of DUET 1 + 2 (n = 604) receiving DRV/r 600/100 mg + OBR and etravirine (ETR) placebo were analysed.
Summary of results
Most common adverse events (AEs) (regardless of causality or severity) were diarrhoea and nausea. Comparing across all trials, there was a lower incidence of overall AEs, serious AEs, discontinuations due to AEs and lipid AEs in naïve pts receiving DRV/r 800/100 mg QD than in treatment-experienced pts using DRV/r 600/100 mg BID. The lower incidence of grade 2-4 at least possibly treatmentrelated diarrhoea with DRV/r compared to LPV/r was seen in both ARTEMIS and TITAN (see table in Figure 1 ). No apparent differences were seen with gender, race or age.
Conclusion
In conclusion, DRV/r was consistently well tolerated and caused significantly less grade 2-4 diarrhoea than LPV/r. In ARTEMIS, the incidence of grade 2-4 diarrhoea and nausea with DRV/r 800/100 mg QD was half that reported with DRV/r 600/100 mg BID in TITAN; this could be related to population, background regimen and/or dosing differences.
